Eli Lilly and Boehringer Ingelheim are gunning for a heart-failure nod for diabetes drug Jardiance. And if they can get it, they want to be able to talk up the product’s effects on exercise ability, too.Original Article
Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise
